VANCOUVER, British Columbia, October 16, 2025--(BUSINESS WIRE)--ME Therapeutics Holdings Inc. ("ME Therapeutics" or the "Company") (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company ...
Chimeric antigen receptor (CAR) T-cell therapy has been used for the treatment of hematological malignancies, but oncologists have been using it less often due to the loss of therapeutic effectiveness ...
T-cell therapy targeting CD22, a protein found on the surface of leukemic cells, was safe and feasible in a small and ongoing study of patients with ALL. T-cell therapy targeting CD22, a protein found ...
Newswise — Philadelphia, January 4, 2022—Aberrant splicing of messenger RNAs encoding surface antigen CD22 leads to downregulation of this protein in pediatric B-lymphoblastic leukemia (B-ALL), ...
Researchers have found that restoration of B cell function in BCR signaling deficiencies involves the interaction of CD22, normally an inhibitory factor, with binding partners on the same cell, which ...
The allogeneic off-the-shelf CD22-directed T-cell product, UCART22, showed early signs of activity and no evidence of unexpected toxicities for adult patients with relapsed/refractory CD22-positive ...
PLEASANTON, Calif. & NANJING, China--(BUSINESS WIRE)--First sentence of release should read: "...has been accepted by the China National Medical Products Administration (NMPA)..." (instead of "...has ...
Please provide your email address to receive an email when new articles are posted on . An investigational chimeric antigen receptor T-cell therapy appeared safe and demonstrated antitumor activity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results